Table 1.
Cytotoxic activity of NRC-03 and NRC-07 against normal human cells in comparison to breast cancer cells
| % Cytotoxicitya | % Hemolysisb | ||||
|---|---|---|---|---|---|
| Treatment | HMECs | Fibroblasts | HUVECs | MDA-MB-231 | Erythrocytes |
| 25 μM NRC-03 | 17 ± 5 | 0 ± 2 | 3 ± 3 | 46 ± 6 | 2 ± 1 |
| 50 μM NRC-03 | 46 ± 3 | 2 ± 1 | 19 ± 2 | 74 ± 4 | 3 ± 2 |
| 25 μM NRC-07 | 20 ± 4 | 1 ± 1 | 7 ± 1 | 29 ± 8 | 1 ± 1 |
| 50 μM NRC-07 | 47 ± 9 | 0 ± 3 | 17 ± 8 | 62 ± 5 | 1 ± 1 |
a, bMean cytotoxic and hemolytic activity ± SEM (n = 3) of NRC-03 or NRC-07 against cultures of normal primary human cells and MDA-MB-231 breast cancer cells, as well as erythrocytes, was determined as described in the Methods section after 24 hours (HMECs, fibroblasts, HUVECs, and erythrocytes) and 8 hours (MDA-MB-231) of exposure to the peptide.